People with multiple sclerosis (MS) have been participants in clinical trials over many years, enabling the development and approval of many treatments for relapsing-remitting MS. Today, people with MS expect to be active collaborators in clinical trials and throughout the research and development process. Researchers and clinicians can benefit from including people with MS in all aspects of research and trials, and are urged to do so, so that we can move forward more quickly in developing needed treatments for progressive MS.
Introduction
In the past 23 years, over a dozen disease-modifying treatments have been approved for relapsing-remitting multiple sclerosis (RRMS), and a great many more have been partially developed and failed to receive approval. All of these development programs required the participation of tens of thousands of people with multiple sclerosis (PwMS) in clinical trials. As the search to find treatments for people with progressive multiple sclerosis (MS) continues, many more participants will need to be recruited.
Today, the expectations of PwMS are evolving, such that they desire to move from being passive trial participants to being active collaborators in the research and clinical trials process-a direction, described by the think tank Faster Cures (http://www.fastercures. org/), as moving "from passengers to co-pilots."
The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) workshop on Advancing Trial Design in Progressive Multiple Sclerosis (Rome, Italy, March 2017) examined topics such as therapeutic targets, patient selection, outcome measures, trial designs, and statistical analysis models. Many challenges exist. This author-a PwMS-advocates that the MS scientific community engage more fully with PwMS, and particularly with those who have progressive disease, in solving the clinical trial challenges that have been raised by the workshop, so that we can move more quickly toward the treatments that people with progressive MS are waiting for.
Involvement of patients in clinical research
Traditionally, patient advocates have been involved in matters of patient rights, patient privacy, informed consent, and education and support of patients and caregivers in managing their disease. Patients were recruited into trials as trial participants. Trials were conducted on their behalf, often without incorporating the needs and views of the participants, and rarely were the results of the trials shared with the study participants. While these approaches generally led directly to positive outcomes for PwMS, patient attitudes are shifting, regulatory expectations are changing and as such the time is right for the MS clinical research community to optimize patient involvement for maximum benefit. PwMS, with appropriate expertise and knowledge, are increasingly becoming full partners with researchers and clinicians in solving the urgent need for treatments for PwMS. An example from the MS community is the Progressive MS Alliance (http://www.progressivemsalliance.org/), which involves PwMS and a caregiver on the Scientific Steering Committee and in project review cycles. This growing trend to understand and incorporate the views and needs of patients in research and clinical trials is being driven by advocacy organizations, regulators, industry, payors, and academic scientists. New organizations have been formed to elicit and include patient perspectives in the process, examples being the Patient-Centered Outcomes Research Institute (PCORI) in the United States (http://www. pcori.org/) and the James Lind Alliance (JLA) in Europe (http://www.jla.nihr.ac.uk/). Regulators (the Food and Drug Administration and the European Medicines Agency) are also collaborating to share best practices for patient engagement (http://www.ema. europa.eu/ema/index.jsp?curl=pages/news_and_ events/news/2016/06/news_detail_002554. jsp&mid=WC0b01ac058004d5c1) and multi stakeholder partnerships have been formed to increase the number of patients having capability to inform drug development (e.g. The European Patients' Academy or EUPATI-https://www.eupati.eu/).
Benefits of greater partnership with patients in clinical research
PwMS can provide a unique perspective throughout the trial process. They bring information and context about the overall condition, its natural course, what endpoints and outcomes are important to them, the impact of the disease on their life, and how they manage it on a daily basis. People with progressive disease often struggle with different symptoms and disabilities than those with relapsing-remitting forms, hence researchers should involve the patient groups that are most relevant to their particular field of study.
This type of patient-centered information and experiential knowledge can be incorporated at various points of the process and brings the patient into the team as a full partner. In the context of clinical trials (the subject of the ECTRIMS workshop), such a partnership can benefit researchers by contributing to framing the research questions to be addressed; shaping and informing the trial design; deciding on and implementing the best strategies for participant recruitment and retention; and increasing dissemination and application of the trial results. The SPRINT-MS trial (https://clinicaltrials.gov/ct2/show/ NCT01982942) is an example of an MS clinical trial that included PwMS as members of the clinical trial steering committee to ensure patient input at all stages of the trial. Outcome measures. The identification of the most appropriate biomarker or outcome measure for assessing progression is required to move the field forward and to measure the effectiveness of treatments. Participants in the ECTRIMS workshop recognized this as a gap and reviewed many of the measures used in MS trials to track the disease and impact of MS on patient function. While gadolinium-enhancing lesions are an excellent surrogate for relapses in RRMS, a similar predictive outcome measure is not available for progressive MS. Although many outcome measures exist, there is no clear best candidate and the use of many different measures makes cross-trial comparisons impossible.
This challenging situation and lack of consensus stymies progress and frustrates PwMS. As a community, we must keep moving forward, despite imperfect measures and insufficient data. One approach, in the interim, should be for the MS community to engage patients' deep insights into the experience of living with MS to identify those measures which most realistically measure the things they care about and which can have potential to provide clinically meaningful information. In particular, PwMS can describe the outcomes and functions that are most important to them such as the multifaceted aspects of physical disability, fatigue and cognitive issues, and the need to measure these aspects continuously, rather than as snapshots in time. Improving these key functions is essential, along with improving overall quality of life and enhancing overall wellness.
Impact on recruiting and retention. MS clinical trials requiring frequent or long batteries of tests negatively impact participant recruitment and especially retention, particularly for people with progressive disease who often experience fatigue and decreased mobility. Involving PwMS, and particularly those with progressive disease, in the design and logistics planning of a study allows for the early identification of challenges that study participants could have in complying with the study requirements and demands. Having such information could, for example, modify the study visit schedule to ensure that participants can realistically comply, thereby reducing screening failures, dropouts, and achieving recruitment goals more quickly. In addition, PwMS can assist in developing materials that describe the trial in terms that participants can understand. This type of input can be used in designing "participant-friendly" informed consent forms that are clear in setting out the risks and benefits of being involved in the trials.
What can be learned from other diseases? The clinical trials process is long and expensive, particularly in progressive MS where (as discussed earlier) no short-term outcome measures are available. In MS therapeutic development, we need to make the trials process more efficient and effective. Adaptive or platform trial designs have been used in other complex diseases, as a method for assessing several treatments simultaneously, with interim assessment of effectiveness and dropping of ineffective treatments. PwMS urgently need to know if a treatment is working for them, regardless of mechanism, and if not they want to move on to another treatment and prevent further disability. Researchers have to balance the ability to run the ideal experiment against the need to get answers in a timely manner. While adaptive designs may have limitations for assessing individual MS treatments, PwMS encourage researchers to work toward finding the most effective treatment (including repurposed treatments). Using creative designs or using crowdsourcing to design and answer specific questions could be a way to bring new approaches to looking at old problems.
Patient expectations for data sharing. MS clinical trials have generated a vast amount of data. The case for sharing this data is clear. In 2014, the Institute of Medicine (IOM) issued a report entitled "Sharing Clinical Trial Data: Maximizing Benefits, Minimizing Risk" (https://www.nap.edu/catalog/18998/sharing-clinical-trial-data-maximizing-benefits-minimizing-risk). The guiding principle in generating the report was "that participants put themselves at risk to participate in clinical trials. The clinical trial community therefore has the responsibility to reward that altruistic behavior by widely sharing the information gathered, so that as much useful knowledge as possible can be wrought from the data." Sharing data inevitably involves risk and challenges, places a burden on sponsors to protect intellectual property and confidentiality, and raises ethical considerations. Nevertheless, the MS community has an abundance of retrospective data that could be used to understand more about the disease process and particularly about progression. Having a plan for sharing data at the start of a clinical trial would also build greater trust between participants and scientists leading to higher recruitment and enrollment. PwMS would urge the MS community to build on initial efforts to share MS clinical trial data, such as the MS Outcomes Assessment Consortium (https://cpath.org/programs/msoac/), and create a more robust culture and atmosphere of data sharing.
Returning results to patients. In addition to more data sharing, patient participants in clinical trials have an increased expectation that they will receive a summary of trial results at the completion of a trial, in language that they can understand. The Multi-Regional Clinical Trials Center of Brigham and Women's Hospital and Harvard (MRCT Center) have, for example, developed guidance and a toolkit for all sponsors (whether industry, non-profit, government, or academic) for this purpose (http://mrct.globalhealth.harvard.edu/return-results).
Like many aspects of data sharing, returning results may help build additional participant engagement in the clinical trial process and, over time, increase public trust by creating greater transparency in the medical research enterprise. Regardless, returning results to trial participants respects their participation and acknowledges their contribution as partners in research.
Conclusion
Patient roles are evolving. A new scientific discipline is emerging, the science of patient involvement. This discipline applies equally across all diseases and aims at understanding and incorporating the perspectives of patients in the process of developing, regulating, and delivering new therapies.
PwMS are highly motivated and increasingly equipped to provide meaningful information into the research and clinical trial process. The entire medical research enterprise can benefit from a greater understanding of what patients need. As the search for new treatments for progressive MS continues, we must embrace this new discipline to improve patient outcomes and quality of life for all PwMS. Researchers and clinicians are urged to involve PwMS in all stages of their research and clinical trials, not only as study subjects but also as collaborators in the design, implementation, analysis, and dissemination of results. The MS community cannot be passive observers as the discipline of patient involvement takes hold. MS scientists and clinicians should become leaders and role models for other diseases and for young scientists as they begin their careers.
